"10.1371_journal.pone.0122609","plos one","2015-05-29T00:00:00Z","Linda Bosserman; Karl Rogers; Carl Willis; Dirk Davidson; Pat Whitworth; Misagh Karimi; Gargi Upadhyaya; James Rutledge; Allan Hallquist; Mathieu Perree; Cary A Presant","Wilshire Oncology Medical Group-US Oncology, La Verne, CA, United States of America; Nashville Oncology Associates, Nashville, TN, United States of America; Tennessee Plateau Oncology, Crossville, TN, United States of America; Nashville Breast Center, Nashville, TN, United States of America; Data Vision, Dayton OH, United States of America; DiaTech Oncology, Montreal, Canada and Nashville, TN, United States of America","Conceived and designed the experiments: LB CP AH JR. Performed the experiments: LB KR CW PW MK GU CP. Analyzed the data: LB KR CW DD PW MK GU JR AH MP CP. Wrote the paper: LB KR CW DD PW MK GU JR AH MP CP.","The authors have the following interests: DiaTech Oncology LLC provided research support by processing the test(s) in the laboratory and providing an independent statistician for analysis of data and results. Dr. Cary Presant is Chief Medical Officer at DiaTech, Dr. Allan Hallquist is Director of Pathology at DiaTech, and Mathieu Perree is Director of Laboratory at DiaTech. Dr. James Rutledge owns Data Vision, Dr. Linda Bosserman is president of Wilshire Oncology Medical Group. Dr. Karemi and Dr. Upadhyaya are employees of Wilshire Oncology. Dr. Presant is an independent contractor under contract with Wilshire Oncology. Dr. Karl Rogers and Dr. Carl Willis are with Nashville Oncology Associates. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.","2015","05","Linda Bosserman","LB",11,TRUE,4,7,11,11,TRUE,TRUE,FALSE,0,NA,FALSE
